文献速递湿疹皮炎与荨麻疹

度普利尤单抗治疗儿童特应性皮炎的长期疗效、安全性与药物生存

Long-Term Effectiveness, Safety, and Survival of Dupilumab in Pediatric Atopic Dermatitis.
PubMed 文献 · JAMA Dermatol · 2026-09-16

荷兰多中心前瞻性BioDay注册研究纳入309例≤16岁中重度特应性皮炎患儿,随访至3年。度普利尤单抗长期维持疾病控制,3年平均EASI为3.4、瘙痒NRS为3.6;最常见不良事件为眼表疾病(36.6%),16.2%停药,3年药物生存率80.1%。

要点

  • 度普利尤单抗在儿童中重度AD中3年维持低疾病活动度和低瘙痒评分
  • 度普利尤单抗相关眼表疾病是最常见不良事件,报告率为36.6%
  • 6个月至5岁患儿瘙痒和QoL评分更高,且更常因给药问题停药

核心结论

  • 度普利尤单抗在临床实践中对儿童AD显示长期有效性和安全性。
  • 年幼儿童瘙痒评分和QoL损害更高,且更常因给药问题停药。

研究设计与样本

  • 多中心前瞻性队列研究(BioDay注册),荷兰4家学术医院和3家非学术医院,2019年11月至2025年10月。
  • 纳入309例≤16岁中重度AD患儿,开始度普利尤单抗治疗并按标签推荐剂量给药。
  • 6个月至5岁51例(16.5%),6-11岁120例(38.8%),12-16岁138例(44.7%)。

主要发现

  • 3年后平均EASI为3.4(95%CI 2.4-4.5),瘙痒NRS为3.6(95%CI 3.1-4.1)。
  • 度普利尤单抗相关眼表疾病报告113例(36.6%),为最常见不良事件。
  • 50例(16.2%)停药,主要因无效19例(38.0%)、不良事件15例(30.0%)或给药问题11例(22.0%)。
  • 3年药物生存率为80.1%。
  • 过敏性哮喘、过敏性鼻炎和6-11岁与较低停药风险相关。

关键数值与推荐

  • 主要疗效指标为EASI和IGA,附加指标包括瘙痒NRS、疼痛NRS和QoL评分。
  • 安全性通过不良事件评估,并分析药物生存、停药原因及相关因素。

临床怎么用

  • 度普利尤单抗可作为儿童中重度AD的长期治疗选择,需关注眼表不良反应。
  • 对年幼患儿应关注瘙痒控制和生活质量,并评估给药可接受性以减少停药。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Limited data are available on the long-term effectiveness and safety of dupilumab in pediatric patients with atopic dermatitis (AD) in a clinical setting. OBJECTIVE: To assess the clinical effectiveness, safety, drug survival, and reasons and associated factors for discontinuation of dupilumab across pediatric age groups with up to 3 years of follow-up. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, prospective cohort study (BioDay Registry) was conducted across 4 academic and 3 nonacademic hospitals in the Netherlands from November 2019 to October 2025 and included pediatric patients (≤16 years) with moderate to severe AD who initiated treatment with dupilumab. Data were analyzed from September 2025 to January 2026. EXPOSURE(S): Dupilumab was administered at the label-recommended dose. Dose reduction was initiated if clinically indicated. MAIN OUTCOMES AND MEASURES: Clinical effectiveness was evaluated by the Eczema Area and Severity Index (EASI) and Investigator Global Assessment (IGA). Additional outcomes included the Numeric Rating Scale (NRS) for pruritus, NRS for pain, and quality of life (QoL) scores. Safety was assessed by adverse events (AEs). Drug survival, reasons, and factors associated with discontinuation were evaluated. RESULTS: Overall, 309 pediatric patients with AD (mean [SD] age, 10.2 [4.2] years; 150 female individuals [48.5%] and 159 male individuals [51.5%]) were treated with dupilumab; 51 (16.5%) were aged 6 months to 5 years (median follow-up, 45.0 [IQR, 26.0-101.0] weeks), 120 (38.8%) were aged 6 to 11 years (median follow-up, 80.0 [IQR, 32.0-135.0] weeks), and 138 (44.7%) were aged 12 to 16 years (median follow-up, 89.5 [IQR, 48.0-143.0] weeks) at baseline. Most patients maintained controlled AD, with mean EASI and NRS scores for pruritus remaining low after 3 years (3.4 [95% CI, 2.4-4.5] and 3.6 [95% CI, 3.1-4.1], respectively). Age groups differed significantly in NRS for pruritus and QoL scores over time, with children aged 6 months to 5 years consistently reporting higher scores than older children. The most frequently reported AE was dupilumab-associated ocular surface disease (113 [36.6%]). Fifty patients (50 [16.2%]) discontinued dupilumab, mainly due to ineffectiveness (19 [38.0%]) and/or AEs (15 [30.0%]), or administration problems (11 [22.0%]); most discontinuations occurred within 1.5 years. Three-year drug survival was 80.1%; allergic asthma, allergic rhinitis, and being age 6 to 11 years were associated with a lower risk of discontinuation. CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that dupilumab demonstrates long-term effectiveness and safety in pediatric AD in a clinical setting. Younger children show higher NRS scores for pruritus and greater QoL impairment and discontinue treatment more often due to administration problems, highlighting age-specific challenges.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Vroman F, Bacos-Cosma OI, Loman L, et al. Long-Term Effectiveness, Safety, and Survival of Dupilumab in Pediatric Atopic Dermatitis. JAMA Dermatol. 2026. PMID: 42747813. doi:10.1001/jamadermatol.2026.3548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。